Bristol-Myers Squibb Company (BMY) reported adjusted earnings per share (EPS) of $1.80 for the third quarter of 2024, which beat the Zacks Consensus Estimate of $1.49.  In the year-ago quarter, BMY had posted an adjusted EPS of $2.Total revenues of $11.9 billion surpassed the Zacks Consensus Estimate of $11.3 billion. The top line also increased 8% from the year-ago period’s level, primarily driven by a strong growth portfolio and an increase in Eliquis sales.BMY’s shares are trading up following the result ...